The Mainz-based biopharmaceutical company BioNTech is halting COVID-19 vaccine production in Germany, closing almost all its ...

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to ...

BioNTech SE plans to halt operations at several manufacturing sites, affecting as many as 1,860 jobs, due to dwindling demand ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American ...

BioNTech slashed its annual guidance by as much as 1 billion euros. It also reduced spending in response to lowered demand for first vaccine doses as well as boosters it developed with Pfizer. However ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

MAINZ, Germany, May 27, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data from select pipeline candidates across the Company’s diversified oncology ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally ...